May 12, 2005

Treatment of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii pneumonia

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Matthew E FalagasArgyris Michalopoulos

Abstract

No abstract listed.

  • References3
  • Citations2

References

  • References3
  • Citations2

Citations

Mentioned in this Paper

Pseudomonas Infections
Inhalation of Drugs
Acinetobacter Infections
Pseudomonas aeruginosa
Pneumonia, Bacterial
Aerosol Dose Form
Acinetobacter baumannii
Drug Resistance, Multiple, Bacterial
Antibiotics
Totazina

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Related Papers

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Matthew E FalagasA Michalopoulos
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
J Garnacho-MonteroJ Madrazo-Osuna
© 2020 Meta ULC. All rights reserved